+1 877 705 1914• 24 / 7
HIPAA Compliant
ISO 27001 Certified

Search Bar & Filters

Found 2 Actively Recruiting clinical trials

P

Actively Recruiting

Researchers are evaluating the safety and effectiveness of tezepelumab in children aged 5 to under 12 years with severe uncontrolled asthma who are already using medium to high doses of inhaled corticosteroids and at least one other asthma controller medication, with or without oral corticosteroids. This phase 3, multicenter, randomized, double-blind study aims to compare tezepelumab with a placebo to better understand its impact on asthma control in this age group. Participants will be randomly assigned in a 21 ratio to receive either subcutaneous injections of tezepelumab or a matching placebo over a 52-week double-blind treatment period. Before treatment, there is a 4 to 6 week screening and run-in period. After the treatment period, a 12-week off-treatment follow-up occurs for those not continuing. Eligible participants may enter an optional 104-week open-label extension to receive tezepelumab with an additional 12-week follow-up after that. During the study, participants will undergo various assessments including lung function tests, asthma symptom tracking, quality of life questionnaires, and blood tests to measure biomarkers and drug levels. Researchers will monitor asthma exacerbations, rescue medication use, and healthcare visits. Safety will be closely observed throughout the study and follow-up periods. Total participation may last over two years for those in the extension phase.

Age: 5Years - 11YearsAll GendersPhase 3
147 locations
C

Actively Recruiting

Researchers are evaluating the treatment of acute watery travelers diarrhea TD by comparing a single dose of rifaximin with loperamide to the current standard treatment of a single dose of azithromycin with loperamide. This Phase 4 randomized controlled trial aims to assess the therapeutic efficacy of these antibiotic regimens combined with loperamide. Participants are active duty military members aged 18 to 60 who have acute watery diarrhea lasting less than 96 hours that affects their daily activities or duties. Participants will be randomly assigned to one of two treatment groups one group receives a single oral dose of rifaximin 550 mg plus loperamide 4 mg initially followed by 2 mg after each unformed stool, not exceeding 16 mg per day for 2 days, and the other group receives a single oral dose of azithromycin 500 mg plus the same loperamide dosing. Both treatments are combined with loperamide as an adjunct therapy. This study uses quadruple masking to maintain objectivity. During the study, participants are asked to provide blood and stool samples at various times to assess infection and immune response. They will also complete daily symptom diaries after treatment and attend follow-up visits with study doctors to monitor illness and recovery. A brief electronic questionnaire will be completed at 3 months. Researchers will measure the primary outcome of therapeutic efficacy up to one week after treatment, along with secondary outcomes such as symptom resolution at 24 and 72 hours, recurrence of illness, and any serious adverse events within 21 days. Participants must be able to follow up for at least 7 days or have arrangements for follow-up elsewhere.

Age: 18Years - 60YearsAll GendersPhase 4
4 locations